Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapy

Fig. 5

Co-mutations in TP53 and ARID1A are associated with inferior clinical outcomes after CAR-T cell therapy. (a) Analysis of co-mutations in r/r MB-NHL. (b) Comparison of response rates of CAR-T cell therapy according to TP53 and ARID1A mutation status. (c) Survival analyses by Kaplan–Meier according to mutation status in patients treated with CAR-T cell therapy

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us